Empagliflozin has been approved in Europe as a treatment for heart failure with reduced ejection fraction.
The SGLT2 inhibitor, sold by Boehringer Ingelheim and Eli Lilly and Company under the name Jardiance, was associated with a significant reduction in the risk of death or hospitalization due to heart failure in the EMPEROR-Reduced trial. This was found to be true for patients with and without type 2 diabetes.
“Jardiance was the first SGLT2 inhibitor to demonstrate cardiovascular protective effects and improve cardiovascular outcomes in patients with type 2 diabetes,” Waheed Jamal, MD, Boehringer Ingelheim’s corporate vice president and head of cardiometabolic medicine, said in a statement. “We are delighted to now be able to offer Jardiance to people with heart failure with reduced ejection fraction, regardless of diabetes status. We look forward to collaborating with regulators in Europe and beyond to ensure access to this trusted therapy.”
Jeff Emmick, MD, PhD, vice president of product development for Eli Lilly and Company, noted in the same statement that results from another key trial are expected later this year.
“This trial will explore empagliflozin in heart failure with preserved ejection fraction, in adults with or without diabetes,” Emmick said. “We are committed to finding solutions for the millions of people who live with heart failure and important metabolic conditions around the world.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.